This company has shut down. Adaptive Phage Therapeutics is no longer operating — its last tracked round was a Series B in 2023.
Explore the Startup GraveyardAdaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.
Adaptive Phage Therapeutics has raised $12.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
Adaptive Phage Therapeutics's investors include Mayo Clinic, Alexandria Venture Investments, Deerfield, U.S. Department of War, Deerfield Capital Management.
Adaptive Phage Therapeutics is headquartered in Bethesda, United States.
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.
Adaptive Phage Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Adaptive Phage Therapeutics — Funding & Investors." VCBacked, June 9, 2023, https://www.vcbacked.co/company/adaptive-phage-therapeutics. Accessed November 11, 2026.
VCBacked. (2023). Adaptive Phage Therapeutics — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/adaptive-phage-therapeutics
{{cite web |title=Adaptive Phage Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adaptive-phage-therapeutics |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Adaptive Phage Therapeutics? Request a listing update